Teresa Binter
Overview
Explore the profile of Teresa Binter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niederle M, Binter T, Riss P, Niederle B, Scheuba C
Ann Surg Oncol
. 2025 Mar;
PMID: 40048031
Background: Pretherapeutic sex-specific basal calcitonin (bCt) cutoff levels and intraoperative diagnosis of desmoplastic stroma reaction (DSR) by frozen section independently facilitate the prediction of lymph-node metastases (LNM) and long-term outcomes...
2.
Niederle M, Binter T, Riss P, Niederle B, Scheuba C
Ann Surg Oncol
. 2025 Feb;
PMID: 40019599
No abstract available.
3.
Feka J, Soliman B, Arikan M, Binter T, Hargitai L, Scheuba C, et al.
Gland Surg
. 2024 Dec;
13(11):1977-1985.
PMID: 39678401
Background: Since 2017, switching from laparoscopic transabdominal adrenalectomy (LTA), posterior retroperitoneoscopic adrenalectomy (RPA) is used as standard procedure in this institution. Aim of this retrospective study was to compare both...
4.
Niederle M, Binter T, Riss P, Niederle B, Scheuba C
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409963
Background: The clinical relevance of clearly defined pretherapeutic basal calcitonin (bCt) cut-offs for predicting lymph node metastases (LNMs) and long-term outcomes (LOs) has so far not been tested in a...
5.
Hargitai L, Boryshchuk D, Arikan M, Binter T, Scheuba C, Riss P
Front Endocrinol (Lausanne)
. 2024 Aug;
15:1442972.
PMID: 39104811
Introduction: Primary hyperparathyroidism (PHPT) is the third most common endocrine disease. With parathyroidectomy, a cure rate of over 95% at initial surgery is reported. Localization of the abnormal parathyroid gland...
6.
Binter T, Baumgartner-Parzer S, Schernthaner-Reiter M, Arikan M, Hargitai L, Niederle M, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339246
The clinical manifestation of multiple endocrine neoplasia type 2 (MEN2) in terms of developing medullary thyroid cancer (MTC), pheochromocytoma (PCC), and/or primary hyperparathyroidism (PHPT) is related to the respective pathogenic...
7.
Arikan M, Hegazy J, Mertlitsch S, Binter T, Hargitai L, Scheuba C, et al.
Ann Surg Oncol
. 2023 Dec;
31(2):1138-1139.
PMID: 38082167
No abstract available.
8.
Arikan M, Hegazy J, Mertlitsch S, Binter T, Hargitai L, Scheuba C, et al.
Ann Surg Oncol
. 2023 Nov;
31(2):1116-1124.
PMID: 37957502
Background: The aim of this study is to define standards for the use of near-infrared autofluorescence (NIRAF)-based overlay imaging via EleVision IR (Medtronic, Dublin, Ireland) and to evaluate its clinical...
9.
Chromy D, Bauer D, Simbrunner B, Jachs M, Hartl L, Schwabl P, et al.
Infect Dis (Lond)
. 2022 Dec;
55(3):189-198.
PMID: 36484317
Background & Aims: Interferon(IFN)-based hepatitis C virus (HCV) therapy has been replaced by direct-acting antivirals (DAAs). We assessed temporal trends in patient characteristics, transmission risks, treatment initiation, and cure rates...
10.
Hartl L, Jachs M, Bauer D, Simbrunner B, Chromy D, Binter T, et al.
J Viral Hepat
. 2022 Sep;
29(12):1062-1072.
PMID: 36062398
The COVID-19 pandemic necessitates healthcare restrictions that also affected ongoing hepatitis C virus (HCV) elimination efforts. We assessed the value of a physician-operated HCV hotline on treatment and cure rates...